Protocol Ledger

NCT06788756 · Phase II/III · RECRUITING

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Interventional Phase II/III clinical trial protocol NCT06788756 sponsored by Moleculin Biotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-12 Enrollment: 312 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06788756
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)312 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06788756
Protocol FieldVerified Registry Value
NCT IdentifierNCT06788756
Consolidated Lead SponsorMoleculin Biotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment312 participants (ESTIMATED)
Registered Start Date2025-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI